Alnylam Pharmace. sell nvestor
Summary
This prediction has just been started. It does not have a price yet.Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w |
---|---|
Alnylam Pharmace. | - |
iShares Core DAX® | 1.560% |
iShares Nasdaq 100 | 0.517% |
iShares Nikkei 225® | 1.730% |
iShares S&P 500 | 1.482% |
Comments by nvestor for this prediction
In the thread Alnylam Pharmace. diskutieren